Austin, TX—On Monday, Dec. 21, 2020, Heart Hospital of Austin became the first facility in Texas to participate in the PROACTIVE-HF clinical trial designed to measure the efficacy of a new remote monitoring device in proactively treating patients with chronic heart failure.
The Cordella™ Pulmonary Artery Pressure Sensor System uses a sensor to detect changes in pulmonary artery pressures, which are then transmitted to managing physicians for detection of heart failure up to two weeks before it occurs. It can also transmit a patient’s vital data, such as weight, blood pressure and pulse oximetry readings, remotely to the monitoring physician.
“With daily pulmonary artery pressure and vital sign data, we are able to make smarter, trend-based clinical decisions before heart failure occurs,” Faisal Syed, M.D., cardiologist at Austin Heart and principal investigator for the study, said. “This allows us to proactively treat patients between office visits, ultimately improving their outcomes.”
Heart failure is a chronic, progressive condition that occurs when the heart is unable to pump an adequate supply of blood to the body. Most patients need therapy treatment to improve their quality of life and reduce advancement of the disease.
The PROACTIVE-HF clinical trial is expected to enroll more than 950 heart failure patients at up to 60 sites across the U.S.